Averix Bio

Averix Bio is the first and only botanical-based cannabinoid research and extraction company in the United States that meets cGMP 21 CFR Part 210 and Part 211 and ICH Q7 compliance. We offer Active Pharmaceutical Ingredient (API) botanical-based CBD Isolate for pre-clinical, clinical, and consumer goods.

Averix Bio has submitted our Drug Master File (DMF) to the US FDA.

The company offers the highest-quality cannabinoid ingredients for use in the pharmaceutical, nutraceutical, veterinary, cosmetic, food, and beverage sectors from our 200,000 square foot facility. Averix Bio ensures consistent quality from seed to shelf, forming the cornerstone of a corporate foundation built on traceability, transparency, and trust. Led by a world-class team with decades of cGMP and pharmaceutical experience, Averix Bio is on a mission to bring healthier cannabinoid-based medical solutions to patients around the world. As a science-first company dedicated to advancing the therapeutic benefits of cannabinoids, our goal is to provide our clients with safe, reliable, and efficacious cannabinoid ingredients they can use to expand their business success. We’re committed to building better health outcomes and promoting industry best practices with integrity and accountability.